Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | RET |
| Variant | C630F |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | RET C630F lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C630F confers a gain of function on the Ret protein as indicated by Ret dimerization and transformation of cultured cells (PMID: 9230192). |
| Associated Drug Resistance | |
| Category Variants Paths |
RET mutant RET act mut RET C630F RET mutant RET C630X RET C630F |
| Transcript | NM_020975.6 |
| gDNA | chr10:g.43114489G>T |
| cDNA | c.1889G>T |
| Protein | p.C630F |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_020630.7 | chr10:g.43114489G>T | c.1889G>T | p.C630F | RefSeq | GRCh38/hg38 |
| NM_001406744.1 | chr10:g.43114489G>T | c.1889G>T | p.C630F | RefSeq | GRCh38/hg38 |
| NM_001406759.1 | chr10:g.43114489G>T | c.1889G>T | p.C630F | RefSeq | GRCh38/hg38 |
| NM_001406760.1 | chr10:g.43114489G>T | c.1889G>T | p.C630F | RefSeq | GRCh38/hg38 |
| NM_020975 | chr10:g.43114489G>T | c.1889G>T | p.C630F | RefSeq | GRCh38/hg38 |
| NM_020630 | chr10:g.43114489G>T | c.1889G>T | p.C630F | RefSeq | GRCh38/hg38 |
| NM_001406743.1 | chr10:g.43114489G>T | c.1889G>T | p.C630F | RefSeq | GRCh38/hg38 |
| NM_020630.5 | chr10:g.43114489G>T | c.1889G>T | p.C630F | RefSeq | GRCh38/hg38 |
| NM_020975.6 | chr10:g.43114489G>T | c.1889G>T | p.C630F | RefSeq | GRCh38/hg38 |
| NM_020975.5 | chr10:g.43114489G>T | c.1889G>T | p.C630F | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET C630F | medullary thyroid carcinoma | sensitive | Selpercatinib | FDA approved - On Companion Diagnostic | Actionable | In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C630F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128). | 32846061 detail... detail... |